Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A

Cancer Gene Therapy

Volumn 10, Issue 10, 2003, Pages 764-770

  Zheng, Jun Ying ^a   Chen, Danlin ^a   Chan, Justin ^a   Yu, Duan ^a   Ko, Eugene ^a   Pang, Shen ^a  

^a UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

DTA; in vivo; Nude mice; Prostate cancer; PSA promoter; Tissue specific

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DIPHTHERIA TOXIN; DISEASE PROGRESSION; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; KIDNEY; LENTIVIRUS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; LENTIVIRUS; MUS MUSCULUS;

EID: 0141919614     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700629     Document Type: Article

References (32)

1. Pang S, Taneja S, Dardashti K, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995;6:1417-1426.
2. Pang S, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR, et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 1997;57:495-499.
3. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000;60:334-341.
4. Rodriguez R, Dannull J, Kaboo R, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
5. Lu Y, Steiner MS. Transcriptionally regulated adenoviruses for prostate-specific gene therapy. World J Urol. 2000; 18:93-101.
6. Shi CX, Hitt M, Ng P, Graham FL. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther. 2002;13:211-224.
7. Naldini L, Blomer U, Galley P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
8. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA. 1996;93:11382-11388.
9. Stewart SA, Poon B, Jowett JB, Xie Y, Chen IS. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci USA. 1999;96: 12039-12043.
10. Uchida N. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA. 1998;95:11939-11944.
11. Ericson C, Wictorin K, Lundberg C. Ex vivo and in vitro studies of transgene expression in rat astrocytes transduced with lentiviral vectors. Exp Neurol. 2002;173:22-30.
12. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol. 1998;72:8150-8157.
13. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873-9880.
14. Yu D, Chen D, Chiu C, Razmazma B, Chow Y-H, Pang S. Prostate-specific targeting using PSA promoter based lentiviral. Cancer Gene Ther. 2001;8:628-635.
15. Pang S. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther. 2000;7:991-996.
16. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res. 1997;9:313-325.
17. Ferrari G, Salvatori G, Rossi C, Cossu G, Mavilio F. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther. 1995;6:733-742.
18. Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology. 1995;214:307-313.
19. Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J Mol Med. 1996;74:379-392.
20. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther. 1997;8:803-815.
21. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991;5:1921-1930.
22. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem. 1996;271:7043-7051.
23. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997;11:148-161.
24. Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999;59:2136-2141.
25. Lee SE, McCadden J, Ferrer F, et al. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res. 2000;20:417-422.
26. Li Y, McCadden J, Ferrer F, et al. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002;62:2576-2582.
27. Pan D, Gunther R, Duan W, et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther. 2002;6: 19-29.
28. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther. 2000;7:20-23.
29. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 2000;7: 910-913.
30. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev. 1993;3:499-503.
31. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci. 1994;716:90-101.
32. Tsai SY, Schillinger K, Ye X. Adenovirus-mediated transfer of regulable gene expression. Curr Opin Mol Ther. 2000;2: 515-523.